🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

Based on findings released by a major medical journal, the new drug cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors treating patients have voiced positive views. The availability of a single-dose, oral treatment like this is hailed as a "revolutionary step" for public health efforts. This is deemed crucial to alleviate the strain of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.